
Challenges and opportunities for innovation in Endometriosis with Dr. Liliane Brunner Halbach
Challenges and opportunities for innovation in Endometriosis
Join us for the second episode of Scailyte’s Endometriosis Awareness Series, where Cinzia Donato interviews Dr. Liliane Brunner Halbach on the “Challenges and opportunities for innovation in endometriosis”.
Dr. Liliane Halbach is an experienced healthcare expert with 20+ years of global experience in drug research and development, global product strategy, and business development. With a MSc in Pharmacy and a PhD in Pharmacology from the University of Basel, Switzerland, she has worked in different roles in headquarters and affiliates of Novartis, Roche, and AstraZeneca in Switzerland, Spain, the US, and Singapore.
In addition to her work in the pharmaceutical industry, Dr. Liliane Halbach has been involved with SPARK, a mentoring program that helps researchers bring ideas to a proof-of-concept stage, since 2012, and now leads SPARK Zurich. Two years ago, she joined the Artemis group, a team of experts from VC and Pharma with the goal to bring more innovation to women’s health. After two years of talking to stakeholders and analyzing the gaps, the group founded Artemis Women’s Health Foundation in February 2023 to connect the ecosystem of investors with innovators and find solutions to the issues observed in women’s health.
In this episode, Dr. Liliane Halbach shares her insights on the challenges and opportunities for innovation in endometriosis. Don’t miss out on this exciting conversation and join us to learn more about the latest developments in the field of endometriosis research and innovation.
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
Recent News
Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals
Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...
Recent News
Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)
Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Scailyte Strengthens Its Leadership
Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...
Recent News
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...
Recent News
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
Recent News
Scailyte and MaxiVAX Solve Clinical Challenges with Data-Driven Collaboration
Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their coll...
Recent News
Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals
Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...
Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)
Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Scailyte Strengthens Its Leadership
Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...
Recent News
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...
Scailyte Extends Series A to USD 8 Million
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...
Recent News
Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs
We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...
Scailyte and MaxiVAX Solve Clinical Challenges with Data-Driven Collaboration
Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their coll...









